Inflammatory carcinoma of the breast – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:23 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Inflammatory carcinoma of the breast – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Pembrolizumab and Cyclophosphamide for Patients with Inflammatory Breast Cancer on the Chest Wall https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-cyclophosphamide-for-patients-with-inflammatory-breast-cancer-on-the-chest-wall/ Wed, 29 Apr 2026 15:01:21 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-cyclophosphamide-for-patients-with-inflammatory-breast-cancer-on-the-chest-wall/ This clinical trial is focused on studying a type of breast cancer known as inflammatory breast cancer that has spread to the chest wall. The study involves two treatments: pembrolizumab, which is a medication that helps the immune system fight cancer, and cyclophosphamide, a chemotherapy drug taken in low doses over a long period. The purpose of the study is to assess how effective these treatments are when used together in patients with this specific type of breast cancer.

Participants in the study will receive both pembrolizumab and cyclophosphamide. Pembrolizumab is given as an infusion, which means it is delivered directly into the bloodstream through a vein, while cyclophosphamide is taken orally as a tablet. The study will last for a period of up to 24 months, during which the effects of the treatment will be monitored. Some participants may receive a placebo instead of one of the medications to help researchers compare the results.

The study aims to understand how well the combination of these treatments works in controlling the cancer and improving the patients’ quality of life. Researchers will look at various outcomes, such as how long patients live without the cancer getting worse and how long the response to the treatment lasts. This information will help determine the potential benefits of using pembrolizumab and cyclophosphamide together for treating inflammatory breast cancer that has spread to the chest wall.

]]> Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ Wed, 29 Apr 2026 14:23:10 +0000 https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ This clinical trial is focused on studying advanced solid tumors, which are types of cancer that have spread beyond their original location and are difficult to treat. The trial will test a new treatment called DS-3939a, which is given as a solution through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein. The purpose of the study is to evaluate the safety and tolerability of DS-3939a and to see how well it works in treating these advanced cancers.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.

]]>